Get the Stockscreener App
21.80
2.50%
-0.56
Urogen Pharma Ltd stock is traded at $21.80, with a volume of 444.68K.
It is down -2.50% in the last 24 hours and down -13.29% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$22.36
Open:
$22.38
24h Volume:
444.68K
Relative Volume:
0.40
Market Cap:
$1.02B
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-5.9401
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
-5.13%
1M Performance:
-13.29%
6M Performance:
+96.75%
1Y Performance:
+90.06%
1-Day Range:
$21.78
$22.66
1-Week Range:
$21.74
$23.74
52-Week Range:
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
21.80 | 1.05B | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Acorn Capital Advisors LLC Has $17.26 Million Stock Holdings in Urogen Pharma $URGN - MarketBeat
Avoiding Lag: Real-Time Signals in (URGN) Movement - news.stocktradersdaily.com
Menora Mivtachim Holdings LTD. Reduces Holdings in Urogen Pharma $URGN - MarketBeat
Urogen Pharma $URGN Shares Purchased by Diadema Partners LP - MarketBeat
Urogen Pharma milestone: first patient treated with new cancer medication - Traders Union
Walleye Capital LLC Takes Position in Urogen Pharma $URGN - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma - The National Law Review
UroGen Pharma (URGN) Issues Stock Units to New Employees - GuruFocus
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - simplywall.st
Panagora Asset Management Inc. Acquires 168,908 Shares of Urogen Pharma $URGN - MarketBeat
Is UroGen Pharma Ltd. (UR8) stock prepared for digital transition2025 Biggest Moves & Free Reliable Trade Execution Plans - Newser
What margin trends mean for UroGen Pharma Ltd. stockJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - Newser
Why UroGen Pharma Ltd. (UR8) stock signals breakout potentialJuly 2025 Fed Impact & Fast Gain Swing Trade Alerts - Newser
Urogen Pharma (NASDAQ:URGN) Trading Down 6.1%What's Next? - MarketBeat
UroGen Pharma Ltd (URGN) Stock Price, Trades & News - GuruFocus
Muscle Invasive Bladder Cancer Market to Reach New Heights - openPR.com
Can UroGen Pharma Ltd. (UR8) stock test all time highs2025 Price Targets & Free Verified High Yield Trade Plans - Newser
UroGen Pharma (URGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Piper Sandler Healthcare Conference - marketscreener.com
Discipline and Rules-Based Execution in URGN Response - news.stocktradersdaily.com
Is UroGen Pharma Ltd. stock oversold or undervaluedJuly 2025 Closing Moves & AI Powered Buy and Sell Recommendations - BỘ NỘI VỤ
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Entropy Technologies LP Buys New Shares in Urogen Pharma $URGN - MarketBeat
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - ADVFN
Urogen Pharma (NASDAQ:URGN) Sets New 12-Month HighHere's Why - MarketBeat
What analysts say about UroGen Pharma Ltd stockEarnings Revision Updates & Free Tremendous Return On Equity - earlytimes.in
UroGen Pharma Ltd (UR8.DU) stock price, news, quote and history - Yahoo Finance UK
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2025 Earnings Call Transcript - MSN
UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Will UroGen Pharma Ltd. stock attract more institutional investors2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
Insider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells 10,000 Shares of Stock - MarketBeat
UroGen Pharma CMO Schoenberg sells $250,000 in shares By Investing.com - Investing.com South Africa
UroGen Pharma CMO Schoenberg sells $250,000 in shares - Investing.com
[Form 4] UroGen Pharma Ltd. Insider Trading Activity - Stock Titan
Does UroGen Pharma Ltd. stock trade at a discount to peersQuarterly Performance Summary & High Accuracy Swing Entry Alerts - newser.com
Will UroGen Pharma Ltd. (UR8) stock sustain dividend payoutsOptions Play & Precise Trade Entry Recommendations - newser.com
Is UroGen Pharma Ltd. (UR8) stock undervalued after correction2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
Urogen Pharma Ltd stock hits 52-week high at 25.2 USD - Investing.com Nigeria
Will UroGen Pharma Ltd. (UR8) stock gain from green policiesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Why global investors buy UroGen Pharma Ltd. (UR8) stockWeekly Market Summary & Safe Capital Allocation Plans - newser.com
Is UroGen Pharma Ltd. (UR8) stock good for long term investing2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):